Rare Disease Therapeutics, Inc.

3 articles about Rare Disease Therapeutics, Inc.

• Rare Disease Therapeutics, Inc. Announces New Expanded FDA Approved Indication for Antivenom ANAVIP® for Treatment of North American Pit Viper Envenomation

  4/5/2021

  Rare Disease Therapeutics, Inc. Announces New Expanded FDA Approved Indication for Antivenom ANAVIP ® for Treatment of North American Pit Viper Envenomation ANAVIP Now Indicated for Management of Adult and Pediatric Patients with All North American Pit Viper Envenomation, Including Rattlesnake, Copperhead, and Cottonmouth/Water Moccasin Bites

• New Antivenom For Rattlesnake Bites Introduced By Rare Disease Therapeutics, Inc.

  10/8/2018

  ANAVIP® [Crotalidae Immune F(ab')2 (Equine)] Reduces late effects of venom

• FDA Green Lights Rare Disease Therapeutics, Inc.'s New Liquid Form To Treat Patients With Acute Lymphoblastic Leukemia (ALL)

  4/30/2014